Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/181172
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHerráez, Rocio-
dc.contributor.authorQuesada, Roberto-
dc.contributor.authorDahdah, Norma-
dc.contributor.authorViñas, Miquel-
dc.contributor.authorVinuesa Aumedes, Teresa-
dc.date.accessioned2021-11-09T18:13:49Z-
dc.date.available2021-11-09T18:13:49Z-
dc.date.issued2021-05-12-
dc.identifier.issn1999-4923-
dc.identifier.urihttp://hdl.handle.net/2445/181172-
dc.description.abstractThe aim of this work was to explore new therapeutic options against Chagas disease by the in vitro analysis of the biocidal activities of several tambjamine and prodiginine derivatives, against the Trypanosoma cruzi CLB strain (DTU TcVI). The compounds were initially screened against epimastigotes. The five more active compounds were assayed in intracellular forms. The tambjamine MM3 and both synthetic and natural prodigiosins displayed the highest trypanocidal profiles, with IC50 values of 4.52, 0.46, and 0.54 µM for epimastigotes and 1.9, 0.57, and 0.1 µM for trypomastigotes/amastigotes, respectively. Moreover, the combination treatment of these molecules with benznidazole showed no synergism. Finally, oxygen consumption inhibition determinations performed using high-resolution respirometry, revealed a potent effect of prodigiosin on parasite respiration (73% of inhibition at ½ IC50), suggesting that its mode of action involves the mitochondria. Moreover, its promising selectivity index (50) pointed out an interesting trypanocidal potential and highlighted the value of prodigiosin as a new candidate to fight Chagas disease.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13050705-
dc.relation.ispartofPharmaceutics, 2021, vol. 13, num. 5, p. 705-
dc.relation.urihttps://doi.org/10.3390/pharmaceutics13050705-
dc.rightscc-by (c) Herráez, Rocio et al., 2021-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationTripanosoma-
dc.subject.classificationMitocondris-
dc.subject.classificationMalaltia de Chagas-
dc.subject.otherTrypanosoma-
dc.subject.otherMitochondria-
dc.subject.otherChagas' disease-
dc.titleTambjamines and prodiginines: biocidal activity against trypanosoma cruzi-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec712740-
dc.date.updated2021-11-09T18:13:49Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid34065993-
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
712740.pdf1.37 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons